Jump to contentSwipe for next articleIndependent Bulletin homepageDownload our appAllNewsSportCultureLifestyleWant to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.Subscribe`; document.body.appendChild(modal); modal.addEventListener('click', () => { document.cookie = 'mos-plan-select=; Max-Age=0; path=/; expires=Thu, 01 Jan 1970 00:00:00 UTC;'; }); modal.querySelector('.subscribe-link')?.addEventListener('click', (e) => { e.preventDefault(); document.cookie = 'mos-plan-select=; Max-Age=0; path=/; expires=Thu, 01 Jan 1970 00:00:00 UTC;'; setTimeout(() => { window.location.href = 'https://www.independent.co.uk/subscribe/app'; }, 500); });});]]>Consumer healthcare company Haleon reported a surge in US sales for over-the-counter products that mitigate side effects caused by popular GLP-1 weight-loss medications like Wegovy and Zepbound.Haleon manufactures products such as Advil, TUMS, and Biotène, which help manage common GLP-1 side effects including nausea, vomiting, diarrhea, constipation, and stomach cramps.The company partnered with CVS Pharmacy to feature its items in dedicated GLP-1 store displays alongside traditional aisles, generating an average 24% sales lift per store during the first quarter.Analytics firm Gallup reports that approximately 11% of individuals in the United States currently take GLP-1 weight-loss medications.Haleon currently holds the majority of GLP-1 shelf space at CVS Pharmacy and has initiated discussions with other major retail chains, including Walmart and Target, to expand its in-store display strategy.In fullWeight loss drug side effects fuel sales boom for Advil-maker HaleonMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in